Cardiac drug-psychotropic drug update.
This is an update from the report-Cardiac Drug and Psychotropic Drug Interactions: Significance and Recommendations-published in this journal in November-December 1999. As mentioned in that article there has been an explosion of new drugs both in psychiatry and cardiology without a sufficient understanding of their potential interactions. Also there is a need for methods to update drug interactions on an ongoing basis. This report describes: 1) examples of actual adverse interactions from clinical cases that move beyond some of the hypothesized contraindications included in the 2000 millennium publication; 2) confirmation of previous adverse interactions reported if they strengthen the earlier findings; 3) listing of new drugs, e.g., sildenafil (viagra) now commonly prescribed by psychiatrists and cardiologists; 4) reports explaining and/or refining mechanisms of adverse interactions; and 5) cautions and important associated phenomenon of either a cardiac or a psychotropic drug, e.g., valproic acid and cases of life-threatening pancreatitis. Methods of publicizing the new knowledge of cardiac drug-psychotropic drug interactions, e.g., the Internet and web sites are described.
Strain
James J
JJ
Division of Behavioral Medicine and Consultation Psychiatry, Mount Sinai-NYU Medical Center/Health System, New York, NY, USA. Jim_Strain@hotmail.com
Karim
Anwarul
A
Caliendo
Gina
G
Alexis
Jeffrey D
JD
Lowe
R Sandlin
RS
Fuster
Valentin
V
D002317:Cardiovascular Agents / Q000145:classification / Q000378:metabolism*; D004347:Drug Interactions; D004357:Drug Synergism; D006801:Humans; D011619:Psychotropic Drugs / Q000145:classification / Q000494:pharmacology*
D002317:Cardiovascular Agents; D011619:Psychotropic Drugs